Clinical Trials Directory

Trials / Completed

CompletedNCT06105424

BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
21 (actual)
Sponsor
RAI Services Company · Industry
Sex
All
Age
30 Years – 50 Years
Healthy volunteers
Accepted

Summary

This will be a single-center, single-blind, four-cohort, 22-day ambulatory study during which up to 24 healthy adult subjects \[6 smokers (SMK), 6 moist snuff consumers (MSC), 6 vapers (VAP), and 6 non-tobacco consumers (NTC)\] will complete 3 measurements of lung permeability. Nasal epithelial cells, sputum, and blood samples will also be collected for current and future biomarker research.

Detailed description

Test Visit 1 will consist of sampling for nasal epithelial cells, sputum, and blood. Additional subjects ("alternates") may be required to complete these procedures to better ensure that 24 subjects are available to complete the lung permeability assessments. During Test Visits 2, 3, and 4, subjects will provide additional blood samples and will complete the lung permeability procedure. A solution containing approximately 40 mCi of a radiolabeled tracer molecule (99mTc-DTPA) will be loaded into a radioaerosol administration system and subjects will breathe the aerosol over approximately 3 minutes, depositing approximately 1 mCi into the lungs (effective dose of approximately 0.3 rem). Subjects will lie supine in front of a gamma counter and a series of images will be obtained over 60 minutes, from which the 99mTc-DTPA clearance rate from the lungs will be calculated.

Conditions

Interventions

TypeNameDescription
PROCEDURELung Permeability AssessmentA gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.

Timeline

Start date
2016-09-24
Primary completion
2016-12-28
Completion
2016-12-28
First posted
2023-10-27
Last updated
2023-10-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06105424. Inclusion in this directory is not an endorsement.